HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Carbutamid
Emedan · U-6987 · Oranil · Bucrol · Burcol · Nadisan · Invenol · Alentin
Identifikatoren & physikalische Daten
| CAS No. | 339-43-5 |
|---|---|
| Summenformel | C11H17N3O3S |
| Durchschnittliche Molmasse | 271,34 g/mol |
| Monoisotopische Masse | 271,09906259 g/mol |
| SMILES | CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1 |
| InChIKey | VDTNNGKXZGSZIP-UHFFFAOYSA-N |
| PubChem CID | 9564 |
| ChEMBL | CHEMBL448570 |
| ChEBI | CHEBI:135118 |
| EC No. | 206-424-4 |
| DTXSID | DTXSID8022741 |
| Lokaler Name | Carbutamid |
Chemische & physikalische Eigenschaften
| XLogP | 1 |
|---|---|
| Polarare Oberfläche (TPSA) | 110 |
| H-Brücken-Donoren | 3 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 18 |
| Formalladung | 0 |
| Komplexität | 356 |
| SpringerMaterials Properties | Crystal structure |
| LogP (Verteilungskoeffizient) | log Kow= 1.011.18 |
| Color/Form | Crystals |
| Löslichkeit | Sol in water at pH 5 to 8.In water, 535 mg/l @ 37 °CDMSO (Slightly), Methanol (Slightly)535.2mg/L(37 ºC) |
| Schmelzpunkt | 144-145 °C144-145° |
| Collision Cross Section | 165.0 Ų [M-H]- [CCS Type: DTBuffer gas: N2Ionization: ESI-Dataset: TOXCASTSource Identifier: DTXSID8022741] |
| Dichte | 1.2840 (rough estimate) |
| Brechungsindex | 1.6630 (estimate) |
| Lagerbedingungen | Refrigerator |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | pKa 5.75(H2O t=25±0.02 I=0.2) (Uncertain) |
| Farbe | Off-White to Pale Beige |
| EPA chemische Informationen | Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]- (339-43-5) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: Human health tier I assessment |
| FDA-Anforderungen | Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392). |
| Hazard Classes and Categories | Skin Irrit. 2 (97.5%) |
| Entsorgungsverfahren | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| Wechselwirkungen | ...SODIUM CARBONATE REDUCED...DRUG'S TERATOGENIC & LETHAL ACTION IN RAT.DRUGS THAT MAY INCR RISK OF HYPOGLYCEMIA FROM SULFONYLUREAS INCL OTHER HYPOGLYCEMIC AGENTS, SULFONAMIDES, PROPRANOLOL, SALICYLATES, CLOFIBRATE, PHENYLBUTAZONE, PROBENECID, DICUMAROL, CHLORAMPHENICOL, MONOAMINE OXIDASE INHIBITORS, & ALCOHOL. /SULFONYLUREAS/ALCOHOL & SALICYLATES BECAUSE OF THEIR DIRECT HYPOGLYCEMIC ACTION, MAY PRECIPITATE HYPOGLYCEMIC COMA IN PT RECEIVING SULFONYLUREAS. ... PROPRANOLOL, BY INTERFERING WITH GLYCOGENOLYSIS & GLUCAGON RELEASE, ENHANCES THE HYPOGLYCEMIC ACTION OF SULFONYLUREAS. /SULFONYLUREAS/THE SULFONYLUREA-MEDIATED SECRETION OF INSULIN CAN BE MODIFIED BY CONCOMITANT PERFUSION OF SECOND DRUG THAT DISPLACES SULFONYLUREA IN PANCREAS. THUS, THE DRUG INTERACTION AT THE TARGET ORGAN OR RECEPTOR SITE SHOULD BE UNDERSTOOD TO PROVIDE ADEQUATE DRUG THERAPY.For more Interactions (Complete) data for 1-BUTYL-3-SULFANILYLUREA (8 total), please visit the HSDB record page. |
Anwendungen & Verwendung
Verwenden
Antidiabetic.